Last reviewed · How we verify
Technescan Mag3 (BETIATIDE)
BETIATIDE (Technescan Mag3), marketed by Curium, is a renal imaging agent used for diagnosing congenital and acquired renal abnormalities. Its key strength lies in its mechanism of being taken up by the kidneys and excreted in the urine, enabling precise imaging of renal function. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | BETIATIDE |
|---|---|
| Sponsor | Curium |
| Drug class | betiatide |
| Modality | Recombinant protein |
| Therapeutic area | Nephrology |
| Phase | FDA-approved |
| First approval | 1990 |
Approved indications
- Diagnosis of congenital and acquired renal abnormalities
- Diagnosis of renal failure
Common side effects
- nausea
- vomiting
- wheezing
- dyspnea
- itching
- rash
- tachycardia
- hypertension
- shaking chills
- fever
- seizure
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |